Telratolimod

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameTelratolimod
Drug Alias Name3M-052MEDI-9197
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionToll like receptor 8 agonistsToll like receptor 7 agonists
TargetsToll like receptor 8Toll like receptor 7
Therapy Area/IndicationsSolid tumoursLymphoma, T-Cell, CutaneousNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesFrance
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator Companies3m Healthcare Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedimmune Llc
Active IndicationsN/A
Inactive IndicationsSolid tumoursLymphoma, T-Cell, CutaneousNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A